With Vascepa’s New CV Claim, Amarin Targets Patients On Other Triglyceride-Lowering Agents
Promotional efforts will include distinguishing icosapent ethyl from fenofibrates, niacin and omega-3 mixtures, which have failed to demonstrate CV risk reduction in clinical studies. Company execs highlight flexibility provided by the US FDA in expanded labeling and dismiss concerns over absence of CV death risk reduction from indication statement.
You may also be interested in...
Amarin – and the industry at large – was stunned in March this year when Hikma and Dr Reddy’s walked away from court with an invalidity ruling against six Vascepa patents in the US. The originator’s CEO gave an impassioned update on the current state of play, including the potential for generics to launch ahead of a Federal Circuit ruling later this year or early in 2021.
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.